Acquired by Medicinal Genomics was acquired by Courtagen Life Science in November 2025, indicating a strategic exit and potential cross-selling or integration opportunities for genomic sequencing and test services within Courtagen’s epilepsy, mitochondrial disease, and autism patient ecosystems.

Regulatory Expertise The company has a dedicated director of regulatory affairs and a history of regulatory collaboration, suggesting readiness to navigate compliance-heavy segments such as cannabis safety testing, dietary supplements, and natural products—verticals that can benefit from compliant workflow automation and validation services.

Cannabis Genome Leader As the first to sequence the cannabis genome and with ongoing cannabis strain sequencing projects, Medicinal Genomics holds strong credibility in cannabis genetics identification and safety, presenting cross-sell opportunities for advanced genomic testing, QA/QC programs, and safety standards in cannabis supply chains.

Automation & Data Integrated automated qPCR microbial testing, in-house DNA sequencing, and a bioinformatics team point to opportunities to offer end-to-end lab automation, cloud-based data analytics, and digital workflow solutions to life sciences customers in supplements, natural products, and food testing.

SMB Focus With a mid-market employee base and revenue in the lower tens of millions, Medicinal Genomics targets growing labs and smaller processors, suggesting sales plays around scalable testing platforms, education workshops, and value-based services for SMEs seeking compliant, fast, and accurate microbial testing.